iBio (NYSEAMERICAN:IBIO) Share Price Crosses Above Fifty Day Moving Average of $0.00

iBio, Inc. (NYSEAMERICAN:IBIO – Get Rating)’s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.00 and traded as high as $0.92. iBio shares last traded at $0.86, with a volume of 272,614 shares changing hands.

Wall Street Analyst Weigh In

Separately, JMP Securities lowered iBio from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 15th.

iBio Trading Down 4.8 %

The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On iBio

Large investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC bought a new position in shares of iBio in the 1st quarter valued at $25,000. US Bancorp DE grew its holdings in iBio by 178.4% during the 1st quarter. US Bancorp DE now owns 67,100 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 43,000 shares during the period. Virtu Financial LLC grew its holdings in iBio by 182.4% during the 2nd quarter. Virtu Financial LLC now owns 121,828 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 78,692 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of iBio in the 4th quarter valued at about $33,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of iBio by 127.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 293,743 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 164,664 shares during the period.

iBio Company Profile

(Get Rating)

iBio, Inc is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins.